Article and Video CATEGORIES

Cancer Journey

Search By

Defining TNM Staging and Early Stage NSCLC
Author
GRACE Videos and Articles
GRACE Cancer Video Library - Lung

GCVL_LU-D01_TNM_Staging_Early_Stage_NSCLC

 

Dr. Eric Vallières, thoracic surgeon, reviews the structure and purpose of staging using the current tumor-node-metastasis (TNM) system for lung cancer.

[

]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

So, the first concept that I would like to cover today is the TNM concept, which is what we use to stage lung cancer, and other cancers, but in lung cancer in particular. We use the T, which stands for tumor, and it’s usually in relation to either the size or the location of the lesion; the N sounds for nodal disease, or nodal involvement, or absence thereof, and the M stands for metastasis, or a tumor that has spread away from its original bed, beyond the lymph nodes and the lymphatics.

GCVL_LU-D01_Figs for TNM_Staging_Early_Stage_NSCLC ML.001

In lung cancer, we subdivide at this stage, and that may change in the years to come, but right now we’re subdividing the T stage, the T descriptor, into 1, 2, 3, and 4, depending on the size of the lesion, depending on the location of the lesion, and whether or not there are other structures involved by the tumor itself, beyond the lungs. For example, if a tumor of the lung is directly invaded into the ribs, which is the chest wall, that is a T3 by definition of the descriptor T3.

GCVL_LU-D01_Figs for TNM_Staging_Early_Stage_NSCLC ML.002

The T1 lesions are the small little lesions that are not invading any structures, and as the tumors grow — so there’s a T, so T2 lesions are lesions that are larger, and T3 as well. The T4 lesions are lesions that are invading into structures that are considered, or historically were considered, to be non-operable, non-surgical, though that has changed over the years, but for a very limited number of patients.

The N descriptor relates, as I said earlier, to whether or not there is tumor into the lymphatics or the lymph nodes in the lung or around the lung, and the N descriptor will either be a 0, a 1, a 2, or a 3. 0 means the lymph nodes were examined, and there was no evidence of cancer in them. If no lymph nodes were examined, if for some reason during surgery there were no lymph nodes removed, the pathologist will put a descriptor X, meaning that we don’t have that information on hand.

GCVL_LU-D01_Figs for TNM_Staging_Early_Stage_NSCLC ML.003b

If the lymph nodes within the lung itself are involved, any number, it’s an N1. Once lymph nodes that are outside the lung are involved, it’s at least an N2, and if those nodes are further away from the lung itself, either on the other side of the midline, or higher up at the root of the neck, it becomes an N3. That’s the highest number that we can put to the nodal descriptor.

The M descriptor relates to a metastasis or not, so M0 means there are none, and M1 means there are. Now we have an M1a, M1b, depending on which areas are affected by metastasis, but in general, the treatment is all the same.

Now, those descriptors, we group them together depending on whether it’s a T1, N0, M0, or a T1, N2, M0, and we group them together and we define a stage. The stage is really what determines how we treat patients, as per established lines of care and standards of care.

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on